包含阿兹夫定的免疫调节剂组合物
By combining azvudine with PD1/PDL1 antibodies as an immunomodulator, the infiltration and activation of immune cells were enhanced, which solved the problem of the insignificant anti-tumor effect of azvudine in immunodeficient mouse models and achieved significant tumor inhibition and enhancement of the immune system.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HENAN GENUINE BIOTECH CO LTD
- Filing Date
- 2023-03-10
- Publication Date
- 2026-07-17
AI Technical Summary
In the existing technology, azvudine is mainly used as an antiviral and antitumor drug, but its immunomodulatory effects are not fully utilized, and its antitumor effect is not significant in immunodeficient mouse models.
By combining azvudine with PD1/PDL1 antibodies, it can be used as an immunomodulator to inhibit tumor progression by regulating immune function, enhancing the infiltration and activation of immune cells, and inhibiting tumor growth by enhancing the immune response and regulating the release of cytokines.
It significantly inhibits tumor growth, enhances the infiltration and activation of immune cells, improves the immune system's ability to attack tumors, strengthens the immune response, regulates the release of cytokines, and enhances the anti-tumor effect.
Smart Images
Figure CN116196325B_ABST